Aviation Medication Transparency Act of 2025

Bill Number: H.R. 2592
Origin Chamber: House
Congress: 119th Congress, Session 1
Policy Area: Transportation and Public Works
Status: Introduced
Latest Action: 2025-04-02: Referred to the House Committee on Transportation and Infrastructure.
Last Updated: 2026-07-03T08:05:42Z

AI-Generated Summary

Purpose

The Aviation Medication Transparency Act of 2025 aims to increase transparency in aviation medical standards by requiring the Federal Aviation Administration (FAA) to publicly share its list of safe medications and treatments for pilots and other certified aviation personnel (known as "airmen"). This helps ensure that airmen and their doctors have clear guidance on what medications are allowed during medical certification, promoting safer and more informed decision-making in the aviation industry.

Key Provisions

Publication Requirement: Within one year of the bill's enactment, the FAA Administrator must publish and maintain an online list (on a public FAA website) of medications and treatments deemed safe for treating certain medical conditions in airmen seeking medical certification.
Consultation Process: The list must be developed in consultation with key groups, including:
The Aeromedical Innovation and Modernization Working Group (a panel advising on aviation health issues).
Representatives of air traffic controllers.
The main organization for airline pilots' unions.
Other relevant stakeholders, such as those involved in recent FAA reauthorization efforts.
List Content and Features:
It must be comprehensive, easy to understand, and accessible (e.g., provided to new airmen when they apply for licenses and certifications).
Include average waiting periods (time off duties) needed to stabilize on approved medications.
Cover medications the FAA has labeled as "Do Not Issue" (prohibited for certification).
Provide a way for doctors or medical providers to ask the FAA questions about the list.
Explain what conditions a medication can or cannot treat, and reasons why a medication is allowed or banned.
Include any other helpful details the FAA deems appropriate.
Updates: The FAA must review and update the list annually, or as needed.

Significant Changes to Existing Law

Prior to this act, the FAA compiled an internal list of medications for airman medical certifications but did not make it publicly available. This bill mandates its publication online, making it accessible to the public for the first time.
It introduces formal consultation requirements with aviation unions and working groups, which were not explicitly required before, and adds annual update obligations to keep the information current.
No major overhauls to certification rules; it focuses on transparency rather than altering approval criteria.

Potential Impacts

On Government Agencies: The FAA will need to dedicate resources to creating, maintaining, and updating the website, as well as handling inquiries from medical providers. This could streamline internal processes by reducing ad-hoc questions about medications.
On Citizens: Airmen (e.g., pilots and air traffic controllers) and their doctors will gain easier access to reliable information, potentially speeding up medical certifications and reducing uncertainty about treatment options. This may improve overall aviation safety by encouraging better compliance with health rules.
On International Relations: Minimal direct impact, though it could indirectly align U.S. aviation standards with global practices by promoting transparent medical guidelines, benefiting international pilots operating in U.S. airspace.

Main Stakeholders Affected

Airmen: Pilots, air traffic controllers, and other certified aviation workers who need medical clearance to perform duties.
Medical Providers: Doctors and healthcare professionals treating airmen, who will use the list to advise on safe prescriptions.
Aviation Unions and Organizations: Groups representing pilots and controllers, involved in consultations and benefiting from clearer rules.
FAA and Regulators: The agency responsible for implementation, facing new administrative duties but gaining tools for better oversight.

Notable Legal, Constitutional, or Political Implications

Legal: Strengthens administrative transparency under existing FAA authority (e.g., from the Federal Aviation Act), without creating new enforcement powers. It may reduce litigation over unclear medication rules by providing official guidance.
Constitutional: No apparent conflicts; it aligns with First Amendment principles of public access to government information and due process in licensing.
Political: Bipartisan support (introduced by representatives from different parties) highlights aviation safety as a non-partisan issue. It could build trust in FAA processes amid ongoing debates on modernizing aviation health standards, potentially influencing future reauthorizations.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Casten, Sean [D-IL-6]

Cosponsors (21)

Rep. Stauber, Pete [R-MN-8], Rep. Balint, Becca [D-VT-At Large], Rep. Lawler, Michael [R-NY-17], Rep. McCollum, Betty [D-MN-4], Rep. McDonald Rivet, Kristen [D-MI-8], Rep. Edwards, Chuck [R-NC-11], Rep. Watson Coleman, Bonnie [D-NJ-12], Rep. Ross, Deborah K. [D-NC-2], Rep. Harder, Josh [D-CA-9], Rep. Kiggans, Jennifer A. [R-VA-2], Rep. De La Cruz, Monica [R-TX-15], Rep. Moore, Blake D. [R-UT-1], Rep. Smith, Adam [D-WA-9], Rep. Suozzi, Thomas R. [D-NY-3], Rep. Subramanyam, Suhas [D-VA-10], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Amo, Gabe [D-RI-1], Rep. Norcross, Donald [D-NJ-1], Rep. McBride, Sarah [D-DE-At Large], Rep. Guest, Michael [R-MS-3], Rep. DeSaulnier, Mark [D-CA-10]

Recent Actions

2025-04-02: Referred to the House Committee on Transportation and Infrastructure.
2025-04-02: Referred to the Subcommittee on Aviation.
2025-04-02: Introduced in House
2025-04-02: Introduced in House

Bill Versions

Aviation Medication Transparency Act of 2025 — issued 2025-04-02 — PDF (3 pages)